Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1969 1
1988 1
1999 1
2000 2
2001 4
2002 5
2003 7
2004 6
2005 3
2006 1
2007 1
2008 3
2009 10
2010 6
2011 8
2012 13
2013 12
2014 13
2015 17
2016 18
2017 11
2018 11
2019 25
2020 29
2021 8
Text availability
Article attribute
Article type
Publication date

Similar articles for PMID: 15277417

187 results
Results by year
Filters applied: . Clear all
Page 1
Improved glycemic control with no weight increase in patients with type 2 diabetes after once-daily treatment with the long-acting glucagon-like peptide 1 analog liraglutide (NN2211): a 12-week, double-blind, randomized, controlled trial.
Madsbad S, Schmitz O, Ranstam J, Jakobsen G, Matthews DR; NN2211-1310 International Study Group. Madsbad S, et al. Diabetes Care. 2004 Jun;27(6):1335-42. doi: 10.2337/diacare.27.6.1335. Diabetes Care. 2004. PMID: 15161785 Clinical Trial.
One week's treatment with the long-acting glucagon-like peptide 1 derivative liraglutide (NN2211) markedly improves 24-h glycemia and alpha- and beta-cell function and reduces endogenous glucose release in patients with type 2 diabetes.
Degn KB, Juhl CB, Sturis J, Jakobsen G, Brock B, Chandramouli V, Rungby J, Landau BR, Schmitz O. Degn KB, et al. Diabetes. 2004 May;53(5):1187-94. doi: 10.2337/diabetes.53.5.1187. Diabetes. 2004. PMID: 15111485 Free article. Clinical Trial.
187 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page